Inside the Buy Canadian Peptides search

NAD+ starts the collection

I would move NAD+ first. Among these four names, it has the most convincing reason to be in every human cell and the least reason to be called a peptide. It is a coenzyme, a helper in the chemistry that releases usable energy from food. Yet it turns up in the same conversations as peptide medicines.

Consider the trial in healthy overweight adults who received nicotinamide riboside. Over eight weeks, blood NAD+ rose by 22%, 51% and 142% across the tested groups. The ingredient was NR, which cells can turn into NAD+. The measurement was NAD+ in blood. Already there are two substances and a particular measurement inside what can sound like one simple claim about NAD+.

It is satisfying to get the nouns right. A result becomes more interesting once it has its proper name. The blood changes were real findings; the later review of human ageing trials describes limited evidence of health benefit and sparse information about NAD+ inside particular tissues. A longer life remains an unproved prospect.

Open the NAD+ entry for the muscle and walking findings, and the separate concerns around infusions.

Four entries, different histories

BPC-157 starts in a stomach-protein sequence. Semaglutide borrows from GLP-1, a gut hormone. Tirzepatide was engineered around GIP and acts at both GIP and GLP-1 receptors. NAD+ already has an everyday job inside cells. A shared shelf hides most of that variety.

I prefer this collection with the differences showing. The BPC-157 ulcer experiments used rats, while the semaglutide kidney trial enrolled people with type 2 diabetes and chronic kidney disease. The biological setting changes the meaning of the result as thoroughly as the compound does.

• BPC-157: stomach origins and repair experiments. The early animal findings deserve a look; the shortage of human trials deserves equal space.
• NAD+: the coenzyme and its precursors. NR, NMN and NAD+ describe different substances, and the human results remain quite specific.
• Semaglutide: heart, kidney and weight studies. Large trials give this entry a substantial human record, alongside substantial cautions.
• Tirzepatide: direct comparisons. Its two-receptor design becomes useful to discuss when the trials supply an actual comparison.

The Canadian label

The word “Canadian” can describe where a claim is being made without telling us much about the compound. It leaves open the chemical identity, the preparation and the approved use. Those details matter before a country name can do much useful work.

There is a particular limit here: the listed references do not establish Health Canada's current position on all four substances. I cannot turn US approval histories into a Canadian answer. Nor can the name of a website establish where any material was made or what it contains.

Canada and categories puts the compounds beside one another and explains the national-approval question. The rest of the collection follows the substances themselves. That is the part of this search I consider worth the trouble.